Follow
Ahmad Halwani
Ahmad Halwani
Huntsman Cancer Institute, University of Utah
Verified email at hci.utah.edu
Title
Cited by
Cited by
Year
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
SM Ansell, AM Lesokhin, I Borrello, A Halwani, EC Scott, M Gutierrez, ...
New England Journal of Medicine 372 (4), 311-319, 2015
34162015
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Journal Clinical Oncology, 2016
8922016
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
YH Kim, M Bagot, L Pinter-Brown, AH Rook, P Porcu, SM Horwitz, ...
The lancet oncology 19 (9), 1192-1204, 2018
3462018
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma
RW Merryman, HT Kim, PL Zinzani, C Carlo-Stella, SM Ansell, ...
Blood, The Journal of the American Society of Hematology 129 (10), 1380-1388, 2017
2212017
Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies
AM Lesokhin, SM Ansell, P Armand, EC Scott, A Halwani, M Gutierrez, ...
Blood, The Journal of the American Society of Hematology 124 (21), 291-291, 2014
1932014
A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma
E Racila, BK Link, WK Weng, TE Witzig, S Ansell, MJ Maurer, J Huang, ...
Clinical Cancer Research 14 (20), 6697-6703, 2008
1772008
Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib
J Jones, MY Choi, AR Mato, RR Furman, MS Davids, LT Heffner, ...
Blood 128 (22), 637, 2016
812016
NCCN guidelines insights: T-cell lymphomas, version 2.2018
SM Horwitz, SM Ansell, WZ Ai, J Barnes, SK Barta, M Choi, MW Clemens, ...
Journal of the National Comprehensive Cancer Network 16 (2), 123-135, 2018
472018
NCCN Guidelines insights: primary cutaneous lymphomas, version 2.2020: featured updates to the NCCN guidelines
N Mehta-Shah, SM Horwitz, S Ansell, WZ Ai, J Barnes, SK Barta, ...
Journal of the National Comprehensive Cancer Network 18 (5), 522-536, 2020
432020
Proposed algorithm for managing ibrutinib-related atrial fibrillation
A Vrontikis, J Carey, JA Gilreath, A Halwani, DM Stephens, ...
Oncology 30 (11), 970-978, 2016
372016
Preliminary results of a phase 1 trial evaluating MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, in patients with CTCL
C Querfeld, T Pacheco, FM Foss, AS Halwani, P Porcu, AG Seto, ...
Blood 128 (22), 1829, 2016
352016
Nivolumab in patients with relapsed or refractory Hodgkin lymphoma-preliminary safety, efficacy and biomarker results of a phase I study
P Armand, SM Ansell, AM Lesokhin, A Halwani, MM Millenson, ...
Blood 124 (21), 289, 2014
272014
Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.
JA Jones, WG Wierda, MY Choi, MS Davids, BD Cheson, RR Furman, ...
Journal of Clinical Oncology 34 (15_suppl), 7519-7519, 2016
252016
Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma …
YH Kim, M Bagot, L Pinter-Brown, AH Rook, P Porcu, SM Horwitz, ...
Blood 130, 817, 2017
242017
Phase 1 Study of the Safety and Efficacy of MRG-106, a Synthetic Inhibitor of microRNA-155, in CTCL Patients
C Querfeld, FM Foss, LC Pinter-Brown, P Porcu, BM William, T Pacheco, ...
Blood 130, 820, 2017
232017
Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells
SS Han, VS Tompkins, DJ Son, NL Kamberos, LL Stunz, A Halwani, ...
Biochemical and biophysical research communications 436 (4), 660-665, 2013
232013
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021: Featured Updates to the NCCN Guidelines
SM Horwitz, S Ansell, WZ Ai, J Barnes, SK Barta, MW Clemens, A Dogan, ...
Journal of the National Comprehensive Cancer Network 18 (11), 1460-1467, 2020
202020
289 Nivolumab in Patients with relapsed or Refractory Hodgkin Lymphoma—Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study
P Armand
56th ASH Annual Meeting and Exposition, Abstracts & Program, San Francisco, CA, 2014
192014
Outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) after treatment with nivolumab for relapsed/refractory Hodgkin lymphoma
P Armand, PL Zinzani, GP Collins, JB Cohen, AS Halwani, C Carlo-Stella, ...
Blood 128 (22), 3502, 2016
182016
The use of natural language processing of infusion notes to identify outpatient infusions
SD Nelson, CC Lu, CC Teng, J Leng, GW Cannon, T He, Q Zeng, ...
Pharmacoepidemiology and Drug Safety 24 (1), 86-92, 2015
172015
The system can't perform the operation now. Try again later.
Articles 1–20